Joining forces to address a major public health challenge

joint-forces-article
To reduce the risk of antibiotic resistance, it is vital to help ensure antibiotics are used only by patients who need them.

Antimicrobial resistance (AMR), which continues to spread rapidly across the globe, is projected to cause more than 10 million deaths annually by 2050.

To address this global challenge, Roche recently entered into a private-public partnership with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HSS).

BARDA oversees the procurement and development of medical countermeasures that address public health and medical consequences of chemical, biological and radiological agents, pandemic influenza and emerging infectious diseases. In order to combat the rise in antibiotic resistance through the development of novel therapeutic and diagnostic approaches, BARDA engages with industry partners.

Joint cost- and expertise-sharing model

The strategic alliance with BARDA will take a portfolio-based approach and provide significant research funding to develop new antibiotics and accelerate the development of tests to detect specific viral and bacterial infections. Under the agreement, BARDA will provide USD 35 million over an initial 27-month period, and potentially up to a total of USD 150 million over five years. Roche will provide significant additional funding and all resources necessary to bring potential new products resulting from the collaboration to the market. 

This partnership will allow us to explore novel development and regulatory pathways and at the same time foster our collaboration with infectious disease experts within the U.S. Government and associated regulatory agencies
Kevin Anderson, leader of the Roche Partnering and Legal team responsible for concluding the agreement with BARDA.
 

Pharmaceutical industry announces new roadmap to combat antimicrobial resistance

Antimicrobial resistance (AMR) threatens to undo decades of progress in combatting disease. On September 21, 2016, the United Nations General Assembly (UNGA) has confronted this issue – only the third time a health topic has been discussed at a high-level UNGA meeting. The session provided a powerful opportunity to organize the global response to AMR and ensure the future sustainability of antibiotics.  Roche and 12 other leading pharmaceutical companies announced a new roadmap laying out four key commitments they will deliver on by 2020 to reduce AMR. The commitments follow the principles identified and agreed upon in the Industry Declaration issued at the 2016 World Economic Forum in Davos earlier this year, and reflect the companies’ intent to continue to proactively contribute to global efforts to address AMR. The key commitments are to:

  • Reduce the environmental impact from the production of antibiotics;
  • Help ensure antibiotics are used only by patients who need them;
  • Improve access to current and future antibiotics, vaccines and diagnostics;
  • Explore new opportunities for open collaborations between industry and the public sector.

Tags: Patients, Society